The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Fibroblast Growth Factor-23 Mitigates Hyperphosphatemia but Accentuates Calcitriol Deficiency in Chronic Kidney Disease
Abstract
Hyperphosphatemia, calcitriol deficiency, and secondary hyperparathyroidism (SHPT) are common complications of chronic kidney disease (CKD). Fibroblast growth factor-23 (FGF-23) is a novel phosphaturic hormone that also inhibits renal 1alpha-hydroxylase activity and thus may be involved in the pathogenesis of SHPT. Several hypotheses were tested: that FGF-23 increases as renal function declines; is linearly associated with serum phosphate levels; is associated with increased phosphaturia independent of parathyroid hormone (PTH); and is associated with decreased calcitriol levels independent of renal function, hyperphosphatemia, and vitamin D stores. FGF-23, PTH, 25(OH)D3, calcitriol, calcium, phosphate, and urinary fractional excretion of phosphate (Fe(PO4)) were measured in 80 CKD patients. Multiple linear regression was used to test the hypotheses. FGF-23 and PTH were inversely associated with estimated GFR (eGFR), whereas calcitriol levels were linearly associated with eGFR. Hyperphosphatemia and hypocalcemia were present in only 12 and 6% of patients, respectively, all of whose eGFR was <30. Increased Fe(PO4) was associated with decreased eGFR, and both increased FGF-23 and PTH were independently associated with increased Fe(PO4). Increased FGF-23 and decreased 25(OH)D3 were independent predictors of decreased calcitriol, but the effects on calcitriol levels of renal function itself and hyperphosphatemia were completely extinguished by adjusting for FGF-23. It is concluded that FGF-23 levels increase early in CKD before the development of serum mineral abnormalities and are independently associated with serum phosphate, Fe(PO4), and calcitriol deficiency. Increased FGF-23 may contribute to maintaining normal serum phosphate levels in the face of advancing CKD but may worsen calcitriol deficiency and thus may be a central factor in the early pathogenesis of SHPT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
Block, G. A., Klassen, P. S., Lazarus, J. M., Ofsthun, N., Lowrie, E. G., & Chertow, G. M. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000133041.27682.a2 · Cited by 2,687
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
Massry, S. G., Coburn, J. W., Chertow, G. M., Hruska, K. A., Langman, C. B., Malluche, H. H., Martin, K. J., McCann, L. M., McCarthy, J. T., Moe, S. M., et al. (2003) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 2,527
FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis
Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., & Yamashita, T. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301264 · Cited by 1,883
Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., & Yamashita, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19081 · Cited by 1,596
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
White, K. E., Evans, W. E., O'Riordan, J. L. H., Speer, M. C., Econs, M. J., Lorenz-Depiereux, B., Grabowski, M., Meitinger, T., & Strom, T. M. (2000) · Nature Genetics · doi:10.1038/81664 · Cited by 1,528
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101545198 · Cited by 1,457
Hypovitaminosis D in Medical Inpatients
Thomas, M. K., Lloyd-Jones, D. M., Thadhani, R. I., Shaw, A. C., Deraska, D. J., Kitch, B. T., Vamvakas, E. C., Dick, I. M., Prince, R. L., & Finkelstein, J. S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803193381201 · Cited by 1,423
GANESH, S. K., STACK, A. G., LEVIN, N. W., HULBERT-SHEARON, T., & PORT, F. K. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v12102131 · Cited by 1,204
Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia
Jonsson, K. B., Zahradnik, R., Larsson, T., White, K. E., Sugimoto, T., Imanishi, Y., Yamamoto, T., Hampson, G., Koshiyama, H., Ljunggren, Ö., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020881 · Cited by 914
NOMOGRAM FOR DERIVATION OF RENAL THRESHOLD PHOSPHATE CONCENTRATION
Walton, R. J., & Bijvoet, O. L. M. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92736-1 · Cited by 886
Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study
Teng, M., Wolf, M., Ofsthun, M. N., Lazarus, J. M., Hernán, M. A., Camargo, C. A., & Thadhani, R. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004070573 · Cited by 782
Self-citationLarsson, T., Nisbeth, U. L. F., Ljunggren, Ö., Jüppner, H., & Jonsson, K. B. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00328.x · Cited by 689
Yamazaki, Y., Okazaki, R., Shibata, M., Hasegawa, Y., Satoh, K., Tajima, T., Takeuchi, Y., Fujita, T., Nakahara, K., Yamashita, T., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021105 · Cited by 671
Sitara, D., Razzaque, M. S., Hesse, M., Yoganathan, S., Taguchi, T., Erben, R. G., J+APw-ppner, H., & Lanske, B. (2004) · Matrix Biology · doi:10.1016/j.matbio.2004.09.007 · Cited by 542
Ferrari, S. L., Bonjour, J.-P., & Rizzoli, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1039 · Cited by 518
Larsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, Ö., Tenenhouse, H. S., Jüppner, H., & Jonsson, K. B. (2004) · Endocrinology · doi:10.1210/en.2003-1768 · Cited by 499
Circulating FGF-23 Is Regulated by 1α,25-Dihydroxyvitamin D3 and Phosphorus in Vivo
Saito, H., Maeda, A., Ohtomo, S.-I., Hirata, M., Kusano, K., Kato, S., Ogata, E., Segawa, H., Miyamoto, K.-I., & Fukushima, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408903200 · Cited by 471
Shimada, T. (2002) · Endocrinology · doi:10.1210/en.143.8.3179 · Cited by 446
Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease
González, E. A., Sachdeva, A., Oliver, D. A., & Martin, K. J. (2004) · American Journal of Nephrology · doi:10.1159/000081023 · Cited by 442
Shimada, T., Urakawa, I., Yamazaki, Y., Hasegawa, H., Hino, R., Yoneya, T., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.102 · Cited by 429
Saito, H., Kusano, K., Kinosaki, M., Ito, H., Hirata, M., Segawa, H., Miyamoto, K.-I., & Fukushima, N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207872200 · Cited by 414
The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin
Eschbach, J. W. (1989) · Kidney International · doi:10.1038/ki.1989.18 · Cited by 408
Portale, A. A., Booth, B. E., Halloran, B. P., & Morris, R. C. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111365 · Cited by 353
FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization
Quarles, L. D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00016.2003 · Cited by 333
Bai, X., Miao, D., Li, J., Goltzman, D., & Karaplis, A. C. (2004) · Endocrinology · doi:10.1210/en.2004-0233 · Cited by 329
Shigematsu, T., Kazama, J. J., Yamashita, T., Fukumoto, S., Hosoya, T., Gejyo, F., & Fukagawa, M. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.04.029 · Cited by 326
FGF-23 in patients with end-stage renal disease on hemodialysis
Imanishi, Y., Inaba, M., Nakatsuka, K., Nagasue, K., Okuno, S., Yoshihara, A., Miura, M., Miyauchi, A., Kobayashi, K., Miki, T., et al. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00604.x · Cited by 272
FGF23 is processed by proprotein convertases but not by PHEX
Benet-Pagès, A., Lorenz-Depiereux, B., Zischka, H., White, K. E., Econs, M. J., & Strom, T. M. (2004) · Bone · doi:10.1016/j.bone.2004.04.002 · Cited by 258
The phosphatonin pathway: New insights in phosphate homeostasis
Schiavi, S. C., & Kumar, R. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00355.x · Cited by 251
PITTS, T. O., PIRAINO, B. H., MITRO, R., CHEN, T. C., SEGRE, G. V., GREENBERG, A., & PUSCHETT, J. B. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-5-876 · Cited by 219
On the Mechanism of Secondary Hyperparathyroidism in Moderate Renal Insufficiency*
Llach, F., & Massry, S. G. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-61-4-601 · Cited by 211
Almaden, Y., Hernandez, A., Torregrosa, V, Canalejo, A., Sabate, L., Fernandez Cruz, L., Campistol, J. M., Torres, A., & Rodriguez, M. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v9101845 · Cited by 191
FGF-23 Is Elevated by Chronic Hyperphosphatemia
Gupta, A., Winer, K., Econs, M. J., Marx, S. J., & Collins, M. T. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0724 · Cited by 168
Mechanisms of secondary hyperparathyroidism
Silver, J., Kilav, R., & Naveh-Many, T. (2002) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00061.2002 · Cited by 167
The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes
Hörl, W. H. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1049 · Cited by 123
Secondary hyperparathyroidism in chronic renal failure: Pathogenic and clinical aspects
Llach, F., & Forero, F. H. V. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.28113 · Cited by 108
Cited by
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027
Self-citationFibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
Gutiérrez, O. M., Mannstadt, M., Isakova, T., Rauh-Hain, J. A., Tamez, H., Shah, A., Smith, K., Lee, H., Thadhani, R., Jüppner, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706130 · Cited by 1,727
Self-citationIsakova, T., on behalf of the Chronic Renal Insufficiency Cohort (CRIC) Study Group, Wahl, P., Vargas, G. S., Gutiérrez, O. M., Scialla, J., Xie, H., Appleby, D., Nessel, L., Bellovich, K., et al. (2011) · Kidney International · doi:10.1038/ki.2011.47 · Cited by 1,266
Self-citationIsakova, T. (2011) · JAMA · doi:10.1001/jama.2011.826 · Cited by 1,020
Self-citationFibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease
Gutiérrez, O. M., Januzzi, J. L., Isakova, T., Laliberte, K., Smith, K., Collerone, G., Sarwar, A., Hoffmann, U., Coglianese, E., Christenson, R., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.844506 · Cited by 837
Self-citation
Metadata
- Authors
- Gutierrez, O., Isakova, T., Rhee, E., Shah, A., Holmes, J., Collerone, G., Ju[Combining Diaeresis]ppner, H., & Wolf, M.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2005-07
- Volume
- 16
- Issue
- 7
- Pages
- 2205-2215
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2170092490
- Cited by
- 921
- References
- 38
- FWCI
- 15.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.